Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $64.35 USD
Change Today +2.35 / 3.79%
Volume 254.7K
RDY On Other Exchanges
Symbol
Exchange
New York
Natl India
Mexico
Frankfurt
As of 8:04 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

doctor reddy's lab-adr (RDY) Key Developments

Dr. Reddy's Laboratories Ltd. Reports Unaudited Standalone and Consolidated Earnings Results for the First Quarter Ended June 30, 2015

Dr. Reddy's Laboratories Ltd. reported unaudited standalone and consolidated earnings results for the first quarter ended June 30, 2015. For the quarter on standalone basis, the company reported net sales/income from operations (net of excise duty) of INR 25,083.3 million against INR 26,528.4 million a year ago. Profit from ordinary activities before other income, finance costs and exceptional items was INR 5,200.3 million against INR 7,049.0 million a year ago. Profit from ordinary activities before tax was INR 5,896.8 million against INR 7,816.8 million a year ago. Net profit for the period was INR 4,758.5 million against INR 6,027.5 million a year ago. Diluted earnings per share were INR 27.81 against INR 35.26 a year ago. For the quarter on consolidated basis, the company reported net income from sales and services of INR 37,577.6 million against INR 35,175.4 million a year ago. Operating profit was INR 7,711.7 million against INR 6,474.5 million a year ago. Profit before tax was INR 7,977.2 million against INR 7,008.8 million a year ago. Net profit attributable to equity holders of the company was INR 6,256.5 million against INR 5,503.9 million a year ago. Diluted earnings per share were INR 36.58 against INR 32.24 a year ago.

Dr. Reddy's Laboratories Ltd., Q1 2016 Earnings Call, Jul 30, 2015

Dr. Reddy's Laboratories Ltd., Q1 2016 Earnings Call, Jul 30, 2015

Dr. Reddy's Laboratories Ltd. Launches Dementia Drug in US

Dr Reddy's Laboratories Ltd. has launched Memantine hydrochloride tablets USP, 5mg and 10mg, which is indicated for the treatment of dementia, in the US. Memantine hydrochloride tablets USP is a therapeutic equivalent generic version of NAMENDA (memantine HCl) tablets approved by the FDA. Dr. Reddy's Memantine hydrochloride tablets USP, 5 mg is available in bottle count size of 60 and the Memantine hydrochloride tablets USP, 10 mg are available in bottle count sizes of 60 and 500.

Dr. Reddy's Laboratories Ltd. Launches Memantine Hydrochloride Tablets USP, 5 Mg and 10 Mg

Dr. Reddy's Laboratories Ltd. announced that it has launched Memantine Hydrochloride tablets USP, 5 mg and 10 mg., a therapeutic equivalent generic vesion of NAMENDA (memantine HCI tables in the US market approved by the United States Food & Administration.

Dr. Reddy's Laboratories Ltd. to Report Q1, 2016 Results on Jul 30, 2015

Dr. Reddy's Laboratories Ltd. announced that they will report Q1, 2016 results on Jul 30, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RDY:US $64.35 USD +2.35

RDY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aurobindo Pharma Ltd 759.90 INR 0.00
Cadila Healthcare Ltd 1,887 INR 0.00
Croda International PLC 3,040 GBp +52.00
Sigma-Aldrich Corp $139.61 USD -0.06
Symrise AG €60.35 EUR +0.352
View Industry Companies
 

Industry Analysis

RDY

Industry Average

Valuation RDY Industry Range
Price/Earnings 30.1x
Price/Sales 4.6x
Price/Book -- Not Meaningful
Price/Cash Flow 30.1x
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DOCTOR REDDY'S LAB-ADR, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.